Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn)

Seminars in Dialysis

Volumn 30, Issue 2, 2017, Pages 142-148

  Stivelman, John C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN;

ANEMIA; CHRONIC KIDNEY FAILURE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HUMAN; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ANEMIA; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85014129169     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12569     Document Type: Article

References (34)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 316(2):73–78, 1987
2. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al.: Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 111(12):992–1000, 1989
3. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(4):S192–S240, 1997 (Suppl. 3)
4. National Kidney Foundation. KDOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 37(1):S182–S238, 2001 Suppl. 1.
5. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(5):S1–S146, 2006 (Suppl. 3)
6. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50(3):471–530, 2007
7. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter Suppl 2(4):279–335, 2012
8. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584–590, 1998
9. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. for the CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085–2098, 2006
10. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, et al., for the TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032, 2009
11. Singh AK: How can erythropoietic stimulating agent use be reduced in chronic dialysis patients? Semin Dial 26(5):531–534, 2013
12. Singh AK, Fishbane S: The optimal hemoglobin in dialysis patients—a critical review. Semin Dial 21(1):1–6, 2008
13. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al.: Secondary analysis of the CHOIR trial epoetin-alfa dose and achieved hemoglobin outcomes. Kidney Int 74(6):791–798, 2008
14. Fishbane S, Besarab A: Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2(6):1274–1282, 2007
15. TM (epoetin alfa), 2011.
16. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents—time for a reevaluation. N Engl J Med 362(3):189–192, 2010
17. U.S. Renal Data System: USRDS 2013 Annual Data Report, Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2013 vol. 2, figure 2.3
18. Singh AK: Is there a deleterious effect of erythropoietin in end-stage renal disease?. Kidney Int 80(6):569–571, 2011
19. Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernan MA: High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int 80(6):663–669, 2011
20. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL: Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD. Am J Kidney Dis 61(1):44–56, 2012
21. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovsedy CP, et al., on behalf of the Dialysis Advisory Group of the American Society of Nephrology: Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 26(6):1238–1247, 2015
22. del Vecchio L, Longhi S, Locatelli F: Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J 9(2):260–267, 2016
23. MacDougall IC, Bircher AJ, Eckardt K-U, Obrador GT, Pollack CA, Stenvinkel P, et al., for Conference Participants: Iron management in chronic kidney disease: conclusions from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int 89(1):28–39, 2016
24. st century. Drugs 76(7):741–757, 2016
25. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, et al.: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13(3):734–744, 2002
26. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, et al.: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15(6):1623–1632, 2004
27. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al.: Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int 87(1):162–168, 2015
28. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16(10):3070–3080, 2005
29. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, et al., for the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators: Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 9(11):1930–1939, 2014
30. EU Clinical Trials Register. Available at https//: www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB accessed September 24, 2016.
31. Ishida JH, Johansen KL: Iron and infection in hemodialysis patients. Semin Dial 27(1):26–36, 2014
32. Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, et al., DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators: Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant 30(4):667–675, 2015
33. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmeyer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24(7):1151–1158, 2013
34. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, et al.: Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 86(4):845–854, 2014